These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1649497)

  • 1. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH; Krämer R; Kwee B; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women.
    Yilmazer M; Fenkci V; Fenkci S; Sonmezer M; Aktepe O; Altindis M; Kurtay G
    Maturitas; 2003 Dec; 46(4):245-53. PubMed ID: 14625121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.
    Cortellaro M; Nencioni T; Boschetti C; Ortolani S; Buzzi F; Francucci B; Caraceni MP; Abelli P; Polvani F; Zanussi C
    Eur J Clin Pharmacol; 1991; 41(6):555-9. PubMed ID: 1667755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause.
    Reginster JY; Christiansen C; Dequinze B; Deroisy R; Gaspard U; Taquet AN; Franchimont P
    Calcif Tissue Int; 1993 Jul; 53(1):13-6. PubMed ID: 8394191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
    Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
    J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
    Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
    Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
    Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.
    Nozaki M; Ogata R; Koera K; Hashimoto K; Nakano H
    Climacteric; 1999 Jun; 2(2):124-30. PubMed ID: 11910665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women.
    Bonduki CE; Lourenço DM; Baracat E; Haidar M; Noguti MA; da Motta EL; Lima GR
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):330-3. PubMed ID: 9539282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
    Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
    Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
    Good WR; John VA; Ramirez M; Higgins JE
    Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.